Literature DB >> 22292413

Evaluation of the toxicity of 2-aminoimidazole antibiofilm agents using both cellular and model organism systems.

Sean D Stowe1, Ashley T Tucker, Richele Thompson, Amanda Piper, Justin J Richards, Steven A Rogers, Laura D Mathies, Christian Melander, John Cavanagh.   

Abstract

Biofilm formation is a ubiquitous bacterial defense mechanism and has been shown to be a primary element in the antibiotic resistance of many human diseases, especially in the case of nosocomial infections. Recently, we have developed several compound libraries that are extremely effective at both dispersing preexisting biofilms and also inhibiting their initial formation. In addition to their antibiofilm properties, some of these molecules are able to resensitize resistant bacterial strains to previously ineffective antibiotics and are being assessed as adjuvants. In this study, we evaluated the toxic effects of three of our most effective 2-aminoimidazole compounds (dihydrosventrin, RA, and SPAR) using a rapid pipeline that combines a series of assays. A methylthiazolyldiphenyl-tetrazolium assay, using the HaCaT keratinocyte cell line was used to determine epidermal irritants and was combined with Caenorhabditis elegans fecundity assays that demonstrated the effects of environmental exposure to various concentrations of these molecules. In each case, the assays showed that the compounds did not exhibit toxicity until they reached well above their current biofilm dispersion/inhibition concentrations. The most effective antibiofilm compound also had significant effects when used in conjunction with several standard antibiotics against resistant bacteria. Consequently, it was further investigated using the C. elegans assay in combination with different antibiotics and was found to maintain the same low level of toxicity as when acting alone, bolstering its candidacy for further testing as an adjuvant.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22292413      PMCID: PMC3434693          DOI: 10.3109/01480545.2011.614620

Source DB:  PubMed          Journal:  Drug Chem Toxicol        ISSN: 0148-0545            Impact factor:   3.356


  35 in total

Review 1.  Bacterial biofilms: a common cause of persistent infections.

Authors:  J W Costerton; P S Stewart; E P Greenberg
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

Review 2.  Bacterial biofilms: an emerging link to disease pathogenesis.

Authors:  Matthew R Parsek; Pradeep K Singh
Journal:  Annu Rev Microbiol       Date:  2003       Impact factor: 15.500

Review 3.  Biofilms as complex differentiated communities.

Authors:  P Stoodley; K Sauer; D G Davies; J W Costerton
Journal:  Annu Rev Microbiol       Date:  2002-01-30       Impact factor: 15.500

4.  Inhibition and dispersion of proteobacterial biofilms.

Authors:  Justin J Richards; Robert W Huigens Iii; T Eric Ballard; Anne Basso; John Cavanagh; Christian Melander
Journal:  Chem Commun (Camb)       Date:  2008-02-08       Impact factor: 6.222

5.  A high-throughput method for assessing chemical toxicity using a Caenorhabditis elegans reproduction assay.

Authors:  Windy A Boyd; Sandra J McBride; Julie R Rice; Daniel W Snyder; Jonathan H Freedman
Journal:  Toxicol Appl Pharmacol       Date:  2010-03-04       Impact factor: 4.219

Review 6.  Finding function in novel targets: C. elegans as a model organism.

Authors:  Titus Kaletta; Michael O Hengartner
Journal:  Nat Rev Drug Discov       Date:  2006-05       Impact factor: 84.694

7.  Amide isosteres of oroidin: assessment of antibiofilm activity and C. elegans toxicity.

Authors:  Justin J Richards; Samuel Reyes; Sean D Stowe; Ashley T Tucker; T Eric Ballard; Laura D Mathies; John Cavanagh; Christian Melander
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

8.  Potential anthelmintics: polyphenols from the tea plant Camellia sinensis L. are lethally toxic to Caenorhabditis elegans.

Authors:  Daisuke Mukai; Noriko Matsuda; Yu Yoshioka; Masashi Sato; Toru Yamasaki
Journal:  J Nat Med       Date:  2008-01-18       Impact factor: 2.343

9.  The genetics of Caenorhabditis elegans.

Authors:  S Brenner
Journal:  Genetics       Date:  1974-05       Impact factor: 4.562

10.  Evaluation of toxic side effects of clinically used skin antiseptics in vitro.

Authors:  Tobias Hirsch; Andreas Koerber; Frank Jacobsen; Joachim Dissemond; Hans-Ulrich Steinau; Sören Gatermann; Sammy Al-Benna; Marco Kesting; Hans-Martin Seipp; Lars Steinstraesser
Journal:  J Surg Res       Date:  2009-05-18       Impact factor: 2.192

View more
  5 in total

1.  Membrane-permeabilizing activity of reverse-amide 2-aminoimidazole antibiofilm agents against Acinetobacter baumannii.

Authors:  Sean D Stowe; Richele J Thompson; Lingling Peng; Zhaoming Su; Meghan S Blackledge; G Logan Draughn; William H Coe; Eva Johannes; Valerie K Lapham; John Mackenzie; Christian Melander; John Cavanagh
Journal:  Curr Drug Deliv       Date:  2015       Impact factor: 2.565

2.  Inhibition and breaking of advanced glycation end-products (AGEs) with bis-2-aminoimidazole derivatives.

Authors:  Mike A Richardson; Robert E Furlani; Brendan K Podell; David F Ackart; Jessica D Haugen; Roberta J Melander; Christian Melander; Randall J Basaraba
Journal:  Tetrahedron Lett       Date:  2015       Impact factor: 2.415

3.  Current Research Approaches to Target Biofilm Infections.

Authors:  Erik van Tilburg Bernardes; Shawn Lewenza; Shauna Reckseidler-Zenteno
Journal:  Postdoc J       Date:  2015-06

Review 4.  Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.

Authors:  Dilara Kiran; Brendan K Podell; Mark Chambers; Randall J Basaraba
Journal:  Semin Immunopathol       Date:  2015-10-28       Impact factor: 9.623

5.  A Pipeline for Screening Small Molecules with Growth Inhibitory Activity against Burkholderia cenocepacia.

Authors:  Carrie Selin; Maria S Stietz; Jan E Blanchard; Sebastian S Gehrke; Sylvain Bernard; Dennis G Hall; Eric D Brown; Silvia T Cardona
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.